SLAMF7 and colitis: Given that SLAMF7-deficient mice exhibited dramatically reduced susceptibility to colitis compared with WT mice and that SLAMF7 activated by recombinant SLAMF7 exacerbates colitis, we expect that blockade of SLAMF7 would relieve intestinal inflammation and have important therapeutic implications.